Yuekang Pharmaceutical announced that the company's subsidiary Yuekang Kechuang recently obtained approval from the US FDA to approve a clinical trial application for YKYY018 nebulized inhaler to treat and prevent human parainfluenza virus infection, IND number 183460. YKYY018 atomized inhaler is an international original membrane fusion inhibitor drug independently developed by the company based on a full-process AI platform. It has previously been approved by the FDA and NMPA to conduct clinical trials on respiratory syncytial virus and human metapulmonary virus infections. Currently, its phase II clinical research on respiratory syncytial virus infection is underway. This approval has further expanded the clinical development layout of this product in the field of respiratory virus infection prevention and treatment, and there is uncertainty about the results of subsequent drug development and approval.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.